In:
Cancer, Wiley, Vol. 126, No. 22 ( 2020-11-15), p. 4826-4837
Abstract:
MET exon 14 alterations and amplifications can be primary oncogenic drivers as well as resistance pathways, such as among patients receiving EGFR targeted therapy. MET exon 14 alterations and amplifications demonstrate different degrees of response to targeted therapy.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
DOI:
10.1002/cncr.v126.22
Language:
English
Publisher:
Wiley
Publication Date:
2020
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
1429-1
Permalink